Research Progress on the Structural Classification and Functional Applications of Lasso Peptides
Lasso peptides, a class of ribosomally synthesized and post-translationally modified peptides (RiPPs), are named for their characteristic interlocked lasso topology.
September 9, 2025
by Xiaonisha
Made-in-China New Drugs: Breaking Through the RMB 4-Billion Battlefield
In 2024, the "Billion-Yuan Club" of made-in-China first-in-class new drugs expanded to 16 members.
September 5, 2025
by lezhi
Research Progress in Drug Therapy for Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by local or systemic inflammatory responses, with insidious onset and high potential morbidity and mortality rates.
September 3, 2025
by Xiaonisha
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China
InnoCare Pharma announced today that the first patient has been dosed in the registrational trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) for patients with BTK inhibitor treated mantle cell lymphoma (MCL) in China.
August 21, 2025
by PharmaSources
Ubiquitin-Proteasome Pathway and Progress in Drug Development
The ubiquitin-proteasome system serves as one of the crucial pathways for the "digestion" of intracellular proteins, regulating numerous vital biological processes such as cell proliferation, differentiation, apoptosis, and DNA repair.
August 13, 2025
by Xiaonisha
Advances in the Research of Targeting B Cells for the Treatment of Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease. The direct cause of SLE pathogenesis lies in the immune imbalance resulting from excessive B-cell activation.
July 25, 2025
by Xiaonisha
Can Myocarditis Lead to Heart Failure? Please Briefly Describe the Research Progress in Drug Treatment for Heart Failure
Recently, there have been online rumors about some recovered COVID-19 "positive" patients who started intense exercise shortly after recovery and then suddenly died due to myocarditis.
July 23, 2025
by Xiaomichong
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
Antengene announced XPOVIO® (selinexor) was approved for commercialization in Indonesia. It's the first XPO1 inhibitor there. Since 2024, it has been approved in multiple APAC markets for various cancer indications.
March 5, 2025
by PR Newswire
Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA
Ascentage Pharma announced that a NDA for its inhouse developed investigational novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575)has been accepted and recommended the Priority Review designation CDE and NMPA.
November 22, 2024
by PR NEWSWIRE
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
November 15, 2024
by PharmaSources
Has the Booming PD-1 Inhibitor Reached its Limit?
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
October 18, 2024
by Krebs Qin
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China
InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.
September 19, 2024
by PharmaSources